Pharvaris NV

PHVS

23.590USD

-0.190-0.80%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

226 / 690

Overall Ranking

344 / 4755

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analysts' Target

Based on 11 analysts

Buy

Current Rating

33.273

Target Price

+38.64%

Upside Space

Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 136.07.

Undervalued

The company’s latest PE is -9.13, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.21M shares, decreasing 2.58% quarter-over-quarter.

Held by Andreas Halvorsen

Star Investor Andreas Halvorsen holds 3.65M shares of this stock.

There is no financial score for this company; the Pharmaceuticals & Medical Research industry's average is 6.80.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Related Indicators

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Related Indicators

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Related Indicators

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Related Indicators

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Related Indicators

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -9.13, which is -37.92% below the recent high of -5.67 and 15.30% above the recent low of -7.74.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimension

P/E

P/B

P/S

P/CF

Industry Ranking 226/690

No Data

The company’s current earnings forecast score is 8.73, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Pharvaris NV is 32.00, with a high of 52.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.73

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.14, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 26.12 and the support level at 20.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.21

Change

-0.07

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-08-27

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 81.51%, representing a quarter-over-quarter decrease of 17.72%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 3.65M shares, representing 5.70% of shares outstanding, with 15.11% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

General Atlantic LLC

7.53M

--

Fidelity Management & Research Company LLC

5.40M

--

Foresite Capital Management, LLC

4.41M

+0.29%

VenBio Partners LLC

4.29M

--

Viking Global Investors LP

Star Investors

3.65M

--

EQT Life Sciences

3.56M

--

Bain Capital Life Sciences Investors, LLC

3.30M

--

VR Adviser, LLC

3.11M

-3.34%

Deerfield Management Company, L.P.

2.02M

--

Commodore Capital LP

1.91M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.23, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is -2.80. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Pharvaris NV

PHVS

4.78 /10

Score

Financial Health

Valuation Dimension

Forecast

Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.64 /10

Score

Financial Health

Valuation Dimension

Forecast

Momentum

Institutional Confidence

Risk Assessment

Zoetis Inc

ZTS

7.56 /10

Score

Financial Health

Valuation Dimension

Forecast

Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.55 /10

Score

Financial Health

Valuation Dimension

Forecast

Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.52 /10

Score

Financial Health

Valuation Dimension

Forecast

Momentum

Institutional Confidence

Risk Assessment

ACADIA Pharmaceuticals Inc

ACAD

7.52 /10

Score

Financial Health

Valuation Dimension

Forecast

Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.